Skip to main content.

Kansas Institute for Precision Medicine External Advisory Committee

Richard Weinshilboum

Richard Weinshilboum, M.D. (Chair of EAC)
Professor of Medicine
Professor of Pharmacology
Mayo Clinic, Rochester, Minnesota

Dr. Weinshilboum received B.A. and M.D. degrees from the University of Kansas, followed by residency training in internal medicine at the Massachusetts General Hospital, a Harvard teaching hospital, in Boston. He was also a pharmacology research associate at the National Institutes of Health in Bethesda, Maryland, in the laboratory of Nobel Laureate Dr. Julius Axelrod. He began his affiliation with the Mayo Medical School and Mayo Clinic in Rochester, Minnesota, in 1972, where he is presently Professor of Molecular Pharmacology & Experimental Therapeutics and Internal Medicine as well as Mary Lou and John H. Dasburg Professor in Cancer Genomics Research. He is Co-PI with his Mayo faculty colleague Dr. Liewei Wang for the over 20 year-running NIH Clinical Pharmacology T32 at Mayo. His research has focused on pharmacogenetics and pharmacogenomics, and he has authored over 470 scientific manuscripts which address those topics.

Howard McLeodHoward L. McLeod, PharmD, is the Executive Clinical Director of Precision Health and Professor of Medicine at Intermountain Healthcare. He is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. Dr McLeod has been recognized as a Fellow of both the American Society of Clinical Oncology and the American College of Clinical Pharmacy. He has also been an active Board Member and/or Founder for over a dozen privately held and publicly traded companies. Howard has published over 600 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance innovative healthcare. Dr. McLeod was a member of the FDA Center for Drug Evaluation and Research (CDER) Committee on Clinical Pharmacology (2002-2013) and the NIH Human Genome Advisory Council (2010-2014). Dr. McLeod was also vice chair for pharmacogenomics for ALLIANCE clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world. He was a founding member of the NHGRI Genomic Medicine Working Group.

Shannon StottShannon Stott, Ph.D.
Associate Professor of Medicine
Department of Medicine, Harvard Medical School
Assistant in Genetics,
Massachusetts General Hospital

Shannon Stott, Ph.D., is a mechanical engineer who has been working at the interface of technology, imaging and medicine. Dr. Stott has a broad background in microfluidics, optics, tissue engineering and cryopreservation, with a focus on their applications in clinical medicine and cell biology. Her group is comprised of bioengineers and chemists focused on translating technological advances to relevant applications in clinical medicine. Specifically, they are interested in using microfluidics and imaging technologies to create tools that increase understanding of cancer biology and of the metastatic process. Dr. Stott will provide input and advice regarding liquid biopsies, precision medicine and engineering.

Susan LunteSusan M. Lunte, Ph.D.
Ralph N. Adams Distinguished Professor of Chemistry and Pharmaceutical Chemistry, University of Kansas
Director of the NIH COBRE Center on Molecular Analysis of Disease Pathways
Director, Adams Institute for Bioanalytical Chemistry

Susan M. Lunte is the Ralph N. Adams Distinguished Professor of Chemistry and Pharmaceutical Chemistry, Director of the Adams Institute for Bioanalytical Chemistry and Director of the NIH COBRE Center for Molecular Analysis of Disease Pathways at the University of Kansas. She received a B.S. degree in chemistry from Kalamazoo College and a Ph.D. in analytical chemistry in 1984 from Purdue University. Dr. Lunte's expertise is in bioanalytical chemistry and microfluidics. She has served as the editor-in-chief of Analytical Methods and was recently chair of the NIH Instrumentation and Systems Development Study Section. She is a fellow of the American Association of Pharmaceutical Scientists, American Chemical Society, Royal Society of Chemistry, American Association for the Advancement of Science and American Institute for Medical and Biological Engineering. Dr. Lunte's research interests include new methodologies for separation and detection of peptides, amino acids, neurotransmitters and pharmaceuticals in biological fluids. She is well versed in microfluidics and running a core focused on microfabrication and brings valuable experience in administering a COBRE grant.

 Alison Motsinger-Reif portraitAlison Motsinger-Reif, Ph.D.
Chief, Biostatistics & Computational Biology Branch and Principal Investigator
National Institute of Environmental Health Sciences

Dr. Alison Motsinger-Reif is the Branch Chief and a Senior Investigator in the Biostatistics and Computational Biology Branch at the NIEHS.  She received her M.S. in Applied Statistics and Ph.D. in Human Genetics – both from Vanderbilt University in 2006 and 2007 respectively.  She was a faculty member at North Carolina State University from 2007-2018, where she built a research program to address important challenges in the “Big Data” space, and received a mid-career endowment.  The primary goal of her research is the development of computational methods to detect genetic risk factors of complex traits in human populations.  As environmental health increasingly accepts a complex model of phenotypic development that involving many genetic and environmental factors, her methods development is focused on strategies that incorporate this complexity.  The methods she develops include artificial intelligence methods such as genetic algorithms, and machine learning tools like neural networks, etc., Her methods and corresponding software tools support are designed to detect gene-gene and gene-environment interactions.  She has published over 190 peer-reviewed publications as a result of this work, in a broad range of journals that reflect the interdisciplinary nature of her work.